THE INCIDENCE AND CLINICAL IMPLICATIONS OF CHROMOTHRIPSIS IN BONE MARROW CELLS OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS)

被引：0
|
作者：
Zemanova, Z. [1 ,2 ]
Michalova, K. [1 ,2 ,3 ]
Brezinova, J. [3 ]
Lhotska, H. [1 ,2 ]
Svobodova, K. [1 ,2 ]
Sarova, I. [1 ,2 ,3 ]
Lizcova, L. [1 ,2 ]
Izakova, S. [1 ,2 ]
Ransdorfova, S. [3 ]
Zdenek, K. [3 ]
Belickova, M. [3 ]
Jonasova, A. [2 ,4 ]
Siskova, M. [2 ,4 ]
Neuwirtova, R. [2 ,4 ]
Cermak, J. [3 ]
机构：
[1] Charles Univ Prague, Gen Univ Hosp, Inst Med Biochem & Lab Diagnost, Ctr Oncocytogenet, Prague, Czech Republic
[2] Charles Univ Prague, Fac Med 1, Prague, Czech Republic
[3] Charles Univ Prague, Gen Univ Hosp, Inst Hematol & Blood Transfus, Prague, Czech Republic
[4] Charles Univ Prague, Med Dept 1, Gen Univ Hosp, Prague, Czech Republic
来源：
HAEMATOLOGICA | 2016年 / 101卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P246
引用
收藏
页码：69 / 70
页数：2
相关论文
共 50 条
  • [31] HYPERPLASIAOF SCHWANN-LIKE CELLS IN THE BONE MARROW OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES
    Chiba, S.
    Cao-Sy, L.
    Sakamoto, T.
    Kato, T.
    Sakata-Yanagimoto, M.
    Nishikii, H.
    Obara, N.
    LEUKEMIA RESEARCH, 2017, 55 : S116 - S116
  • [32] Bone marrow immune microenviroment in patients with myelodysplastic syndromes
    Tsakiraki, Z.
    Papageorgiou, S.
    Spathis, A.
    Gouloumis, A. R.
    Pouliakis, A.
    Bouchla, A.
    Thomopoulos, T.
    Angelopoulou, E.
    Panayiotides, I.
    Pappa, V.
    Foukas, P.
    VIRCHOWS ARCHIV, 2021, 479 (SUPPL 1) : S116 - S116
  • [33] Clinical Experience of Decitabine in Elderly Patients with Myelodysplastic Syndromes (MDS)
    Geils, George F., Jr.
    BLOOD, 2009, 114 (22) : 1092 - 1092
  • [34] Autologous bone marrow transplantation (ABMT) with marrow purged by mafosfamide in thirteen patients with myelodysplastic syndromes (MDS) in acute myeloblastic transformation (AML-MDS).
    Laporte, JP
    Isnard, F
    Lesage, S
    Douay, L
    Najman, A
    Gorin, NC
    BLOOD, 1995, 86 (10) : 3802 - 3802
  • [35] Marrow stromal cells are not derived from the malignant clone in myelodysplastic syndromes (MDS).
    Awaya, N
    Rupert, K
    Bryant, E
    Torok-Storb, B
    BLOOD, 2001, 98 (11) : 353A - 353A
  • [36] BONE-MARROW BIOPSY IN RAEB AND RAEB-T MYELODYSPLASTIC SYNDROMES (MDS)
    DELILIERS, GL
    SOLIGO, D
    ANNALORO, C
    RIVA, A
    MAIOLO, AT
    BLUT, 1988, 56 (06): : C21 - C21
  • [37] Comparison of Peripheral Blood and Bone Marrow Molecular Profiling in Primary Myelodysplastic Syndromes (MDS)
    Mohamedali, Azim M.
    Gaken, Joop
    Ahmed, Momin
    Kulasekararaj, Austin
    Smith, Alexander E.
    Malik, Farook
    Mufti, Ghulam
    BLOOD, 2014, 124 (21)
  • [38] Bone marrow hypocellularity and normal karyotype are the best prognostic factors in myelodysplastic syndromes (MDS)
    Pecorari, P
    Orlandini, D
    Sceusa, R
    BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 : 872 - 872
  • [39] Unrelated donor marrow transplantation for myelodysplastic syndromes (MDS).
    CastroMalaspina, H
    Collins, JER
    Gajewski, J
    Harris, R
    Ramsay, N
    Deeg, HJ
    BLOOD, 1997, 90 (10) : 465 - 465
  • [40] Biologic and clinical implications of marrow culture studies in the myelodysplastic syndromes
    Greenberg, PL
    SEMINARS IN HEMATOLOGY, 1996, 33 (02) : 163 - 175
12345